S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:AUTL

Autolus Therapeutics Stock Forecast, Price & News

$6.43
+0.32 (+5.24%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.97
$6.55
50-Day Range
$5.54
$7.12
52-Week Range
$4.60
$12.23
Volume
524,652 shs
Average Volume
1.23 million shs
Market Capitalization
$468.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.57
30 days | 90 days | 365 days | Advanced Chart
Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Autolus Therapeutics logo

About Autolus Therapeutics

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Headlines

Why Autolus Therapeutics Stock Jumped 25% Today
November 9, 2021 |  finance.yahoo.com
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $5.56
November 8, 2021 |  americanbankingnews.com
Autolus Stock Rallies On $250M Investment From Blackstone
November 8, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUTL
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.72 million
Book Value
$4.01 per share

Profitability

Net Income
$-142.09 million
Net Margins
-5,610.45%
Pretax Margin
-6,512.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$468.87 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

1045th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

160th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

How has Autolus Therapeutics' stock been impacted by Coronavirus?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have decreased by 5.0% and is now trading at $6.43.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Autolus Therapeutics?

Autolus Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,500,000 shares, an increase of 39.7% from the October 31st total of 1,790,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 2.3 days.
View Autolus Therapeutics' Short Interest
.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Autolus Therapeutics
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.04. Autolus Therapeutics had a negative net margin of 5,610.45% and a negative trailing twelve-month return on equity of 55.22%. During the same period in the previous year, the firm earned ($0.72) EPS.
View Autolus Therapeutics' earnings history
.

What price target have analysts set for AUTL?

6 brokers have issued 12-month price targets for Autolus Therapeutics' shares. Their forecasts range from $9.00 to $21.00. On average, they expect Autolus Therapeutics' share price to reach $14.67 in the next twelve months. This suggests a possible upside of 128.1% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Christian Martin Itin, Chief Executive Officer & Director
  • Christopher Vann, Chief Operating Officer & Senior Vice President
  • Andrew J. Oakley, Chief Financial Officer & Senior Vice President
  • Martin Pulé, Chief Scientific Officer & Senior Vice President
  • David Brochu, Chief Technical Officer & Senior Vice President

What other stocks do shareholders of Autolus Therapeutics own?

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering (IPO) on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (1.94%), Millennium Management LLC (0.61%), Eversept Partners LP (0.55%), Morgan Stanley (0.27%), Granahan Investment Management Inc. MA (0.24%) and MYDA Advisors LLC (0.24%).

Which institutional investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Millennium Management LLC, Granahan Investment Management Inc. MA, Morgan Stanley, Eversept Partners LP, UBS Group AG, and Lindbrook Capital LLC.

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was purchased by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Cetera Investment Advisers, BlackRock Inc., MYDA Advisors LLC, Citadel Advisors LLC, GSA Capital Partners LLP, Jump Financial LLC, and Brighton Jones LLC.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $6.43.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $468.87 million and generates $1.72 million in revenue each year. The company earns $-142.09 million in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 2,020 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

Where are Autolus Therapeutics' headquarters?

Autolus Therapeutics is headquartered at FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 442038296230 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.